Mansoor Raza Mirza
About Mansoor Raza Mirza
Mansoor Raza Mirza, M.D., age 64, is an independent director of Sera Prognostics and has served on the board since December 2014; he was nominated for re‑election as a Class I director at the 2025 annual meeting for a term expiring in 2028 . A medical and radiation oncologist specializing in non‑surgical treatment of gynecologic cancers, he became Chief Medical Officer of Acrivon Therapeutics in April 2025 and continues to hold senior clinical roles in Denmark; his credentials include leading roles in international oncology organizations, extensive trial leadership, and authorship of consensus guidelines, with education from Pirogov Moscow State Medical Institute and postgraduate certifications from the University of Southern Denmark . The board has affirmatively determined Dr. Mirza is independent under Nasdaq standards .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| European Society of Gynaecological Oncology (ESGO) | Vice-President | 2020–2024 | Leadership in gynecologic oncology policy and collaboration |
| European Network of Gynaecological Oncological Trial Groups | Chairman (former) | Not disclosed | Led multi-group trial coordination and strategy |
| Gynecologic Cancer InterGroup | Executive Director | Not disclosed | International trial coordination and oversight |
| Danish Gynecological Cancer Society | Vice-Chairman | Not disclosed | National leadership in gynecologic cancer |
| Independent Data Safety Monitoring Committees | Member | Not disclosed | Trial safety oversight on multiple international studies |
| ASCO/ESMO | Invited Speaker (“Meet the Professor,” “Presidential Symposium”) | Not disclosed | Thought leadership in oncology |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Acrivon Therapeutics, Inc. | Chief Medical Officer | Since Apr 2025 | Pharmaceutical company CMO role |
| Karyopharm Therapeutics Inc. | Director; Clinical Consultant | Consultant since 2010; current director (date not specified) | Public biopharma board; clinical advisor |
| Copenhagen University Hospital (Rigshospitalet) | Chief Oncologist | Current | Clinical leadership |
| Nordic Society of Gynaecological Oncology | Medical Director | Through Oct 2025 | Regional oncology leadership |
Board Governance
- Independence: Board determined Dr. Mirza (and all committee members) are independent under Nasdaq standards .
- Tenure and election: Director since 2014; nominated in 2025 as Class I for term through 2028 .
- Committee assignment: Nominating & Governance Committee member; committee met twice in 2024 . He is not listed as a member of Audit or Compensation committees .
- Board leadership: Chair and CEO roles are separated; Kim Kamdar is Board Chair .
- Attendance: In 2024 the board met nine times; each director attended at least 75% of board and applicable committee meetings .
- Board size and classification: Board transitioning to nine members immediately prior to the 2025 meeting; three‑class staggered structure .
Fixed Compensation
| Year | Cash Fees | Board Retainer (Policy) | Committee Fees (Policy) | Notes |
|---|---|---|---|---|
| 2024 | $39,000 | $35,000 annual board retainer | Nominating & Governance member fee $4,000; chair $8,000 | Mirza is a Nominating & Governance member (not chair) |
Performance Compensation
| Element | Grant Date Fair Value (2024) | Vesting | Option Terms | Performance Metrics |
|---|---|---|---|---|
| RSU Award | $60,000 | “Subsequent Award” vests in 12 monthly installments over 1 year | N/A | None disclosed; director equity vesting is time-based |
| Stock Option Award | $60,000 | “Subsequent Award” vests in 12 monthly installments over 1 year | 10-year max term; strike = FMV at grant | None disclosed; director equity vesting is time-based |
The non‑employee director compensation policy targets an annual equity grant with ~$120,000 grant date fair value split between options and RSUs (“Subsequent Award”), aligning with Mirza’s 2024 RSU and option award values .
Other Directorships & Interlocks
| Company | Role | Committees | Potential Interlock/Conflict |
|---|---|---|---|
| Karyopharm Therapeutics Inc. | Director; Clinical Consultant | Not disclosed | No SERA related‑party transactions disclosed involving Karyopharm |
| Acrivon Therapeutics, Inc. | Chief Medical Officer | Not disclosed | No SERA related‑party transactions disclosed involving Acrivon |
- Related‑party oversight: SERA’s audit committee must pre‑approve related‑party transactions ≥$120,000; 2023–2025 disclosures include Real Endpoints (linked to another director), but do not include Mirza‐related transactions .
Expertise & Qualifications
- Medical and radiation oncologist focused on gynecologic cancers; extensive protocol development and trial conduct/regulatory experience .
- Author of phase 1–3 studies, including those leading to FDA and EMA registrations; published in NEJM and Lancet .
- Leadership in ESGO/ENGOT/GCIG; DSMC experience; invited speaker at ASCO/ESMO; Prix Galien jury member .
- Education: M.D., Diploma in Surgery, Diploma in Clinical Oncology (Pirogov Moscow State Medical Institute); postgraduate certification in radiation and medical oncology (University of Southern Denmark) .
Equity Ownership
| Component | Amount | Detail |
|---|---|---|
| Common shares held | 42,106 | Direct holdings |
| RSUs vesting within 60 days (as of Mar 31, 2025) | 1,186 | Counted in beneficial ownership |
| Total RSUs held (as of Dec 31, 2024) | 3,559 | Aggregate RSUs outstanding |
| Options exercisable within 60 days (as of Mar 31, 2025) | 222,610 | Counted in beneficial ownership |
| Total options held (as of Dec 31, 2024) | 261,038 | Aggregate options outstanding |
| Total beneficial ownership | 265,902 shares; <1% of outstanding | Based on 37,663,771 shares outstanding (Class A + B) as of Mar 31, 2025 |
| Shares outstanding (reference) | 37,663,771 | Denominator for % ownership |
No pledging or hedging disclosures for Mirza are cited in the proxy; SERA maintains a Corporate Code of Conduct and Ethics and an Insider Trading Policy (sections referenced in the proxy) .
Governance Assessment
- Strengths: Independent status; long tenure (since 2014) offering continuity; strong domain expertise in gynecologic oncology; equity‑linked director compensation that aligns with shareholder outcomes via RSUs and options .
- Engagement: Nominating & Governance Committee member; committee met twice in 2024; overall board met nine times and all directors met at least 75% attendance threshold .
- Alignment: Holds options and RSUs in addition to common shares; annual equity grants vest monthly, indicating ongoing alignment without short‑term performance triggers .
- Potential risks/RED FLAGS to monitor: Multiple external roles (Acrivon CMO; Karyopharm director/consultant) increase time‑commitment and potential conflict surface—though no related‑party transactions involving Mirza were disclosed for 2023–2025, continued audit committee oversight is important if SERA engages clinically or commercially with those companies .
- Structural governance: Board separation of Chair and CEO enhances independent oversight; robust related‑party review policy and indemnification agreements are in place .